Ann: Long Covid-19 Collaboration Outcomes Presentation, page-68

Well let's talk about the announcement...

Provisional patent applications have been filed in the United States (US) to seek protection for these
new inventions
• A potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified
as suggestive of its therapeutic potential as a treatment for Long COVID-19

We know what that biomarker is and ATL1102 already effective with this one makes it very attractive. As we have discussed no safety data would be required. Straight to the trials. I think it would be pretty fast tracked.


• Collaboration with global leader in the clinical research of neurological aspects of Long COVID-19 Dr
Koralnik to continue with application for grant funding

Dr K as we all know is pretty big name with it comes to Covid and Long covid. One of the biggest research centre in the world. He is applying for grant funding. What are the chances of refusal. Data with biomarkers will attract plenty of Pharmas . Funding won't be much of an issue.


• Company plans to review its new patent applications with targeted pharmaceutical and diagnostic
companies for potential commercial discussions

It's the other way. Let it hit the headlines and Pharma would be chasing us. DMD trial in EU will also get great exposure.

Edison group has been recruited on time for a reason. Obviously Nasdaq listing is on cards.

Glh..Imo dyor